1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Oncocross Co., Ltd.

Oncocross Co., Ltd.

KKRX:382150
3,065.00
KRW
+25.00
(+0.82%)
-518.28EPS
46.59BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
101.51
18.64
17.11
10.27
102.37
30.99
32.71
Basic EPS, GAAP
-829
-1,413
-14,460
-2,451
-1,162
-473
-619
-747
-540.81
Free Cash Flow per Basic Share
-865.63
-1,403.88
-3,487.79
-1,223.65
-972.54
-553.41
-543.99
-897.8
-791.41
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-22.58
-80.39
-1,136.84
942.37
395.95
1,390.36
1,725.17
1,096.45
1,112.04
Tangible Book Value per Share
-24.61
-85.22
-1,140.68
937.51
391.68
1,386.38
1,721.98
1,092.49
1,107.44
Basic Weighted Avg Shares
1
1
1
5
9
9
10
12
12
Sales/Revenue/Turnover
- -
- -
90
100
150
92
1,072
370
395
Operating Margin (%)
- -
- -
-3,843.58
-7,339.31
-6,655.3
-7,440.64
-649.58
-2,383.65
-2,473
Depreciation Expense
56
73
166
258
369
438
407
810
1,072
Net Income, GAAP
-684
-1,176
-12,821
-13,146
-10,204
-4,214
-6,483
-8,929
-6,539
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-14,245.58
-13,146.17
-6,791.63
-4,604.7
-604.66
-2,410.17
-1,653.24
Working Capital
-104
2,640
934
12,543
3,607
15,664
19,252
18,457
8,122
LT Debt
- -
347
70
- -
116
- -
243
5,083
111
Total Equity
-268
-953
-13,481
11,175
4,695
16,487
20,457
13,372
13,562
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-128.6
-39.79
-35.1
-52.79
-42.57

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
277
205
8,827
LT Borrowings
5,040
8,162
- -
LT Finance Leases
43
31
111
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
116,837
89,640
46,589

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
24,212
28,132
26,769
Cash, Cash Equivalents & STI
23,433
27,247
25,167
Accounts Receivable, Net
45
77
33
Inventories
- -
- -
- -
Total Current Liabilities
5,754
7,495
18,647
Payables & Accruals
- -
- -
- -
ST Debt
277
205
8,827
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-0.05%
-34.63%
Free Cash Flow
- -
40.8%
88.35%
Net Income, GAAP
- -
2.6%
37.72%
Sales/Revenue/Turnover
- -
205.66%
-65.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
60
174
183
655
1,072
2025
63
138
29
141
370
2026
167
58
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-142
-131
-132
-192
-619
2025
-190
-148
-170.27
-238.65
-747
2026
-216.84
83
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yi Rang Kim
Full Time Employees
40
Sector
Health technology
Industry
Pharmaceuticals: major
Address
16F, 11, Saechang-ro, Mapo-gu Seoul SL South Korea 04168
IPO Date
Dec 18, 2024
Website
oncocross.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Oncocross Co., Ltd. is a South Korean biotechnology company specializing in AI-powered drug development, focusing on treatments for cancers, rare diseases, and intractable diseases. Founded in 2015 and headquartered in Seoul, the company leverages its proprietary transcriptome data-based AI platform, RAPTOR AI™, to identify optimal disease indications and companion diagnostic biomarkers for anti-cancer drugs, accelerate drug development processes, and reduce time and costs by predicting additional drug indications. Its drug pipeline includes candidates such as OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e targeting cancer metastasis inhibition; OC211, a Pan-KRAS inhibitor; OC221, an immuno-oncology combination; OC514 for amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 for atopic dermatitis, alongside development efforts in metabolic and cardiovascular diseases. Recently, Oncocross has expanded its strategic collaboration with JW Pharmaceutical to jointly develop new anticancer and regenerative medicine drugs utilizing its AI platform, RAPTOR AI™, enhancing discovery and validation of novel indications and expediting clinical trial success potential. Additionally, Oncocross completed a significant IPO in December 2024, raising approximately KRW 85.56 billion (USD 59.5 million), marking a major financial milestone supporting its growth and research initiatives. The company operates primarily within South Korea and maintains partnerships with pharmaceutical companies, research institutes, and biotech firms to advance drug discovery and development efficiently through artificial intelligence technology.